Literature DB >> 20631488

Development of the interdisciplinary evidence-based s3 guideline for the diagnosis and treatment of prostate cancer: methodological challenges and solutions.

Christoph Röllig1, Monika Nothacker, Achim Wöckel, Susanne Weinbrenner, Manfred Wirth, Ina Kopp, Günter Ollenschläger, Lothar Weissbach.   

Abstract

Evidence-based guidelines are important sources of knowledge in everyday clinical practice. In 2005, the German Society for Urology decided to develop a highquality evidence-based guideline for the early detection, diagnosis and treatment of the different clinical manifestations of prostate cancer. The guideline project started in 2005 and involved 75 experts from 10 different medical societies or medical organizations including a patient organization. The guideline was issued in September 2009 and consists of 8 chapters, 170 recommendations, and 42 statements. Due to the broad spectrum of clinical questions covered by the guideline and the high number of participating organizations and authors, the organizers faced several methodological and organizational challenges. This article describes the methods used in the development of the guideline and highlights critical points and challenges in the development process. Strategies to overcome these problems are suggested which might be beneficial in the development of new evidence-based guidelines in the future. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20631488     DOI: 10.1159/000315762

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  2 in total

1.  [Patient centeredness and decision-making in localised prostate cancer: possible fields of health services research in urology].

Authors:  J Huber; A Ihrig; C G Huber; B Hadaschik; S Pahernik; M Hohenfellner
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

2.  Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data.

Authors:  Semaw Ferede Abera; Ahmed Bedir; André Glowka; Dirk Vordermark; Daniel Medenwald
Journal:  BMC Cancer       Date:  2022-06-07       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.